A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Latest Information Update: 09 May 2025
At a glance
- Drugs Izalontamab brengitecan (Primary)
- Indications Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 15 Oct 2024 Planned End Date changed from 1 Aug 2024 to 1 Jun 2025.
- 15 Oct 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Jun 2025.
- 09 Sep 2024 According to SystImmune media release, data from the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 taking place on September 13-17 in Barcelona, Spain.